Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

It is the second trial to show an OS benefit with Keytruda when used in the adjuvant setting after the KEYNOTE-671 study in non-small cell lung cancer (NSCLC), said MSD, known as Merck & Co in ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...